◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › VRTX

Vertex Pharmaceuticals Inc (VRTX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Biotechnology · DATA UPDATED 2026-07-12

Vertex Pharmaceuticals Inc (VRTX) operates in the Biotechnology industry and is headquartered in Boston, United States with about 6,400 employees. Its market capitalization is roughly $121 billion. In the fiscal year ended 2025-12-31, VRTX reported $12.1B in revenue and $4.0B in net income.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.

Interactive charts & full statements → Open the VRTX valuation workbench →

VRTX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$12.3B	$12.1B	$11.0B	$9.9B	$8.9B	$7.6B	$6.2B	$4.2B	$3.0B	$2.5B	$1.7B	$1.0B	$580M	$1.2B	$1.5B	$1.4B	$143M	$102M	$176M	$199M	$216M
Gross Profit	$10.6B	$10.3B	$9.5B	$8.6B	$7.8B	$6.7B	$5.5B	$3.6B	$2.6B	$2.2B	$1.5B	$907M	$519M	$1.1B	$1.2B	$1.3B	$131M	$88M	$160M	$185M	$204M
Gross Margin %	86.3%	85.0%	86.1%	87.2%	87.9%	88.1%	88.1%	86.8%	86.6%	88.9%	87.6%	87.8%	89.5%	89.2%	81.7%	94.3%	91.1%	86.1%	91.1%	93.0%	94.4%
Operating Income (EBIT)	$4.8B	$4.8B	($233M)	$3.8B	$4.3B	$2.8B	$2.9B	$1.2B	$635M	$123M	$10M	($469M)	($692M)	($903M)	$2M	$114M	($696M)	($613M)	($463M)	($420M)	($229M)
Operating Margin %	39.0%	39.4%	-2.1%	38.8%	48.2%	36.7%	46.0%	28.8%	20.8%	5.0%	0.6%	-45.4%	-119.3%	-74.5%	0.1%	8.1%	-485.5%	-601.1%	-263.6%	-210.9%	-105.9%
Net Income	$4.3B	$4.0B	($536M)	$3.6B	$3.3B	$2.3B	$2.7B	$1.2B	$2.1B	$263M	($112M)	($558M)	($739M)	($445M)	($107M)	$30M	($755M)	($642M)	($460M)	($391M)	($207M)
Net Margin %	35.4%	32.7%	-4.9%	36.7%	37.2%	30.9%	43.7%	28.3%	68.8%	10.6%	-6.6%	-54.1%	-127.2%	-36.7%	-7.0%	2.1%	-526.3%	-628.7%	-262.0%	-196.6%	-95.6%
EBITDA	$5.4B	$4.9B	$486M	$4.6B	$4.4B	$2.9B	$3.3B	$1.6B	$707M	$103M	$75M	($411M)	($599M)	($555M)	$42M	$134M	($705M)	($599M)	($426M)	($385M)	($200M)
Earnings Per Share (EPS)	$16.87	$15.32	$-2.08	$13.89	$12.82	$9.01	$10.30	$4.51	$8.09	$1.04	$-0.46	$-2.31	$-3.14	$-1.98	$-0.50	$0.14	$-3.77	$-3.70	$-3.27	$-3.03	$-1.83
Shares Outstanding (M)	256M	258M	258M	260M	259M	260M	263M	261M	259M	253M	245M	241M	235M	225M	212M	209M	200M	173M	141M	129M	113M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRTX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$3.0B	$3.2B	$3.1B	$3.0B	$2.8B	$2.9B	$2.8B	$2.6B
Gross Profit	$2.6B	$2.8B	$2.7B	$2.6B	$2.4B	$2.5B	$2.4B	$2.3B
Gross Margin %	86.9%	85.6%	86.5%	86.2%	86.9%	85.5%	85.8%	85.9%
Operating Income (EBIT)	$1.1B	$1.3B	$1.2B	$1.2B	$630M	$1.0B	$1.1B	($3.5B)
Operating Margin %	38.1%	40.3%	38.6%	38.8%	22.8%	35.2%	40.3%	-132.8%
Net Income	$1.0B	$1.2B	$1.1B	$1.0B	$646M	$913M	$1.0B	($3.6B)
Net Margin %	34.5%	36.9%	35.2%	34.8%	23.3%	31.4%	37.7%	-135.8%
EBITDA	$1.3B	$1.4B	$1.4B	$1.3B	$782M	$1.2B	$1.3B	($3.3B)
Earnings Per Share (EPS)	$4.02	$4.65	$4.20	$3.99	$2.49	$3.50	$4.01	$-13.92
Shares Outstanding (M)	256M	256M	258M	259M	260M	260M	261M	258M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRTX Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$4.2B	$3.6B	($493M)	$3.5B	$4.1B	$2.6B	$3.3B	$1.6B	$1.3B	$845M	$236M	($365M)	($513M)	($52M)	$268M	$144M	($635M)	($428M)	($226M)	($252M)	($22M)
Capital Expenditures (CapEx)	$530M	$438M	$298M	$258M	$205M	$235M	$260M	$75M	$96M	$259M	$57M	$45M	$51M	$51M	$71M	$95M	$38M	$23M	$32M	$32M	$32M
Free Cash Flow (FCF)	$3.7B	$3.2B	($790M)	$3.3B	$3.9B	$2.4B	$3.0B	$1.5B	$1.2B	$586M	$180M	($411M)	($564M)	($103M)	$197M	$49M	($673M)	($451M)	($259M)	($285M)	($55M)
FCF Margin %	30.3%	26.5%	-7.2%	33.2%	44.0%	31.8%	48.2%	35.9%	38.6%	23.5%	10.5%	-39.8%	-97.2%	-8.5%	12.9%	3.5%	-469.8%	-442.0%	-147.4%	-143.2%	-25.4%
Dividends Paid	—	—	—	—	—	$102M	$265M	$10M	$21M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$291M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRTX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$1.4B	$498M	$1.2B	$1.1B	$819M	$585M	$1.4B	($3.8B)
Capital Expenditures (CapEx)	$133M	$149M	$102M	$146M	$41M	$93M	$68M	$77M
Free Cash Flow (FCF)	$1.3B	$349M	$1.1B	$927M	$778M	$492M	$1.3B	($3.8B)
FCF Margin %	43.4%	10.8%	37.0%	31.3%	28.1%	16.9%	47.0%	-144.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VRTX Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$26.5B	$26.1B	$22.5B	$22.7B	$18.2B	$13.4B	$11.8B	$8.3B	$6.2B	$3.5B	$2.9B	$2.5B	$2.3B	$2.3B	$2.8B	$2.2B	$1.7B	$2.0B	$980M	$601M	$922M
Cash & Cash Equivalents	$5.5B	$5.1B	$4.6B	$10.4B	$10.5B	$6.8B	$6.0B	$3.1B	$2.6B	$1.7B	$1.2B	$715M	$625M	$569M	$489M	$475M	$243M	$447M	$389M	$356M	$213M
Total Liabilities	$7.1B	$7.5B	$6.1B	$5.2B	$4.2B	$3.3B	$3.1B	$2.2B	$1.8B	$1.5B	$1.6B	$1.4B	$1.2B	$963M	$1.5B	$1.2B	$1.2B	$859M	$742M	$330M	$416M
Total Debt (Short + Long-Term)	$0M	$83M	$92M	$84M	$89M	$80M	$42M	$39M	$572M	$586M	$806M	$784M	$786M	$458M	$682M	$651M	$537M	$186M	$393M	$20M	$124M
Total Shareholders' Equity	$19.4B	$18.7B	$16.4B	$17.6B	$13.9B	$10.1B	$8.7B	$6.1B	$4.4B	$2.0B	$1.3B	$1.1B	$1.1B	$1.4B	$1.2B	$966M	$504M	$1.1B	$239M	$271M	$506M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VRTX viewer.

Other Companies in Biotechnology

ABBV · AbbVie — $458 billion
AMGN · Amgen — $203 billion
GILD · Gilead Sciences — $161 billion
REGN · Regeneron Pharmaceuticals — $69 billion
BIIB · Biogen — $30 billion
ROIV · Roivant Sciences Ltd. — $26 billion
INSM · Insmed Incorporated — $26 billion
INCY · Incyte — $24 billion

← VRTS All stocks VRXA →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.